Skip to contentA
Alnylam Pharmaceuticals, Inc.
A
ALNYAlnylam Pharmaceuticals, Inc. Q2 2017 · 10-Q
Revenue$15.93M$15.93Mno prior Q2 2016 on file Net Income-$118.42M-$118.42MN/M vs Q2 2016 EPS Diluted-$1.34-$1.34N/M vs Q2 2016 Operating Income-$120,474,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Alnylam Pharmaceuticals, Inc. · CIK 1178670 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$102,700,000N/M Margins · derivedOperating margin-756.2%
Net margin-743.3%
ended Jun 30, 2017 · filed Aug 9, 2017 · 40 d after period end